Anna Mestre Borras,Hanna Mehari,Stefan Ståhl et al.
Anna Mestre Borras et al.
Antibody prodrugs provide a strategy to reduce systemic toxicity by masking therapeutic antibodies until activation in specific physiological environments. Nivolumab, an anti-PD-1 checkpoint inhibitor used in cancer immunotherapy, can cause...
Integrating machine learning tools in protein design: a case of MHETase engineering for PET biodeconstruction [0.03%]
Rommel Santiago Granja-Travez,Taraka Dale,Ramesh K Jha
Rommel Santiago Granja-Travez
The integration of machine learning tools into protein engineering offers substantial promise, yet linking computational predictions to experimental performance remains challenging. Here, we applied accessible computational platforms to eng...
Zachary T Baumer,Timothy A Whitehead
Zachary T Baumer
T7 RNA polymerase (T7 RNAP) is a foundational enzyme for biotechnology, but its utility for many potential applications is limited by low thermal stability of 43-44°C. While stabilized variants exist, the most stable commercial version has...
Bind, catalyze, and quantify: a modern protein and enzyme engineering toolbox of genetically encoded non-canonical amino acids [0.03%]
绑定、催化和量化：基于遗传密码扩展的非标准氨基酸现代蛋白质及酶工程技术集锦
Søren C Spina,Joe Bailey,Blaise Kimmel
Søren C Spina
Non-canonical amino acids (ncAAs) are versatile molecular building blocks that can enhance nearly every aspect of protein engineering, from improving binding affinity to enabling precise quantitative analyses. This review highlights advance...
Expansion of the known Poly(Aspartic Acid) Hydrolases through the Identification of Four New PahZ1 Homologs [0.03%]
通过鉴定四种新的PahZ1同源物扩展已知的聚天冬氨酸酶类群
Justin D Marsee,Chad A Brambley,Thi Ho et al.
Justin D Marsee et al.
Polyaspartic acid (PAA) is a biodegradable polymer with various industrial applications. To date there are only three known PAA hydrolases (from the gene PahZ) capable of degrading PAA . These enzymes are expressed in two different bacteria...
Usage of a split CH2 domain as building block for new antibody formats [0.03%]
一种用于新型抗体构建模块的分裂型CH2结构域及其应用
Thomas Langer,Ingo Focken,Christian Lange et al.
Thomas Langer et al.
Antibodies, and in particular bi- or multispecific antibodies, are the most promising candidates for new therapy options in cancer or inflammatory diseases. So far, multiple different antibody variants containing only distinct parts of anti...
Experimental Analyses of RFdiffusion Designed Miniproteins for Binding to SARS-CoV-2 Nucleocapsid Protein [0.03%]
用于结合SARS-CoV-2核蛋白的RFdiffusion设计的迷你蛋白质的实验分析
Zeenat Khakerwala,Ashwani Kumar,Sujay S Gaikwad et al.
Zeenat Khakerwala et al.
Miniprotein designs are emerging as promising antibody alternatives for therapeutic and diagnostic use. Using RFdiffusion, we designed 538 binder candidates targeting both N- and C-terminal domains of the SARS-CoV-2 nucleocapsid protein, se...
Brian Cieslewicz,Cullen Roeder,Dara Bree et al.
Brian Cieslewicz et al.
Several technologies leverage avidin/biotin interactions for complexation including the MAPS vaccine technology which utilizes rhizavidin, a biotin-binding protein derived from the proteobacterium Rhizobium etli, to complex antigens with bi...
VIF-Ig: A novel Fc framework for ADCC by incorporation of VHH unit [0.03%]
一种新型的ADCC效应Fc框架（VIF-Ig）：通过嵌合纳米抗体可变区片段实现
Yaohui Li,Yichen Huang,Yingdan Duan et al.
Yaohui Li et al.
Antibody-dependent cellular cytotoxicity is a key mechanism for antibody-based therapeutics, and current engineering strategies to enhance ADCC primarily rely on two approaches: Fc mutations to improve the antibody's intrinsic CD16a affinit...
Rapid Isolation and Characterization of High-Affinity Single-Domain Antibodies for Broad-Spectrum Detection of SARS-CoV-2 Variants [0.03%]
快速分离和表征高亲和力单域抗体以检测SARS-CoV-2变异毒株
Ah Hyun Cho,Hee Eon Lee,Ji Hyun Lee et al.
Ah Hyun Cho et al.
The rapid evolution of SARS-CoV-2 presents substantial challenges to maintaining diagnostic accuracy. Single-domain antibodies (variable domains of camelid heavy-chain antibodies, VHHs), commonly referred to as nanobodies, are attractive to...